These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 20368739)

  • 1. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.
    Lim JS; Mietus-Snyder M; Valente A; Schwarz JM; Lustig RH
    Nat Rev Gastroenterol Hepatol; 2010 May; 7(5):251-64. PubMed ID: 20368739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
    Softic S; Cohen DE; Kahn CR
    Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soft drinks consumption and nonalcoholic fatty liver disease.
    Nseir W; Nassar F; Assy N
    World J Gastroenterol; 2010 Jun; 16(21):2579-88. PubMed ID: 20518077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.
    Nomura K; Yamanouchi T
    J Nutr Biochem; 2012 Mar; 23(3):203-8. PubMed ID: 22129639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
    Ouyang X; Cirillo P; Sautin Y; McCall S; Bruchette JL; Diehl AM; Johnson RJ; Abdelmalek MF
    J Hepatol; 2008 Jun; 48(6):993-9. PubMed ID: 18395287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fructose and NAFLD: metabolic implications and models of induction in rats.
    Castro GS; Cardoso JF; Vannucchi H; Zucoloto S; Jordão AA
    Acta Cir Bras; 2011; 26 Suppl 2():45-50. PubMed ID: 22030814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nonalcoholic fatty liver disease].
    Ko JS
    Korean J Gastroenterol; 2010 Jul; 56(1):6-14. PubMed ID: 20664312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition.
    Sapp V; Gaffney L; EauClaire SF; Matthews RP
    Hepatology; 2014 Nov; 60(5):1581-92. PubMed ID: 25043405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.
    DiStefano JK
    Cell Mol Life Sci; 2020 Jun; 77(11):2079-2090. PubMed ID: 31760464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and management issues for non-alcoholic fatty liver disease.
    Duvnjak M; Lerotić I; Barsić N; Tomasić V; Virović Jukić L; Velagić V
    World J Gastroenterol; 2007 Sep; 13(34):4539-50. PubMed ID: 17729403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
    Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
    Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
    Vilà L; Rebollo A; Ađalsteisson GS; Alegret M; Merlos M; Roglans N; Laguna JC
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):32-40. PubMed ID: 21122807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content.
    Siddiqui RA; Xu Z; Harvey KA; Pavlina TM; Becker MJ; Zaloga GP
    Nutr Metab (Lond); 2015; 12():41. PubMed ID: 26583036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review.
    Coronati M; Baratta F; Pastori D; Ferro D; Angelico F; Del Ben M
    Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Carnitine counteracts in vitro fructose-induced hepatic steatosis through targeting oxidative stress markers.
    Montesano A; Senesi P; Vacante F; Mollica G; Benedini S; Mariotti M; Luzi L; Terruzzi I
    J Endocrinol Invest; 2020 Apr; 43(4):493-503. PubMed ID: 31705397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose and NAFLD: The Multifaceted Aspects of  Fructose Metabolism.
    Jegatheesan P; De Bandt JP
    Nutrients; 2017 Mar; 9(3):. PubMed ID: 28273805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.